Korro Bio, Inc. (KRRO) Operating Margin
- Operating margin · 12 months: Value -4625.48%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -4625.48% | Operating income / revenue. Period ending 2026-06-30. $-110.18M ÷ $2.38M × 100 ≈ -4625.48% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -110.18M USD | Operating Income (Loss) |
| Revenue | 2.38M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 52.24M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-110.18M | $2.38M | (m) | $52.24M | (m) | -4625.48% |
| 2026-03-31 | $-117.27M | $3.84M | (m) | $58.79M | (m) | -3052.34% |
| 2025-12-31 | $-121.86M | $6.39M | (m) | $65.58M | (m) | -1906.37% |
| 2025-09-30 | $-94.50M | $7.37M | (m) | $71.55M | (m) | -1282.04% |
| 2025-06-30 | $-98.55M | $6.28M | (m) | $73.70M | (m) | -1569.08% |
| 2025-03-31 | $-95.48M | $4.82M | (m) | $69.80M | (m) | -1980.44% |
| 2024-12-31 | $-91.91M | $2.27M | (m) | $63.64M | (m) | -4047.12% |
| 2024-09-30 | $-95.76M | (m) | (m) | $62.10M | (m) | (m) |
| 2024-06-30 | $-91.62M | (m) | (m) | $60.14M | (m) | (m) |
| 2024-03-31 | $-85.90M | (m) | (m) | $56.13M | (m) | (m) |
| 2023-12-31 | $-84.53M | (m) | (m) | $57.25M | (m) | (m) |
| 2023-09-30 | $-63.20M | (m) | (m) | $29.16M | (m) | (m) |
| 2023-06-30 | $-70.81M | (m) | (m) | $38.31M | (m) | (m) |
| 2023-03-31 | $-80.25M | (m) | (m) | $46.99M | (m) | (m) |
| 2022-12-31 | $-83.00M | $0.00 | (m) | $49.42M | (m) | (m) |
| 2022-09-30 | $-86.17M | $0.00 | (m) | $51.52M | (m) | (m) |
| 2022-06-30 | $-90.88M | $0.00 | (m) | $55.47M | (m) | (m) |
| 2022-03-31 | $-87.09M | $9.42M | (m) | $59.60M | (m) | -924.82% |
| 2021-12-31 | $-84.03M | $14.07M | (m) | $60.92M | (m) | -597.32% |
| 2021-09-30 | $-72.95M | $24.02M | (m) | $60.00M | (m) | -303.73% |
| 2021-06-30 | $-53.38M | $35.27M | (m) | $54.49M | (m) | -151.36% |
| 2021-03-31 | $-42.09M | $34.37M | (m) | $45.85M | (m) | -122.47% |
| 2020-12-31 | $-27.55M | $36.98M | (m) | $37.41M | (m) | -74.49% |
| 2020-09-30 | $-23.76M | $31.74M | (m) | $31.78M | (m) | -74.85% |
| 2020-06-30 | $-19.59M | $44.73M | (m) | $26.85M | (m) | -43.80% |
| 2020-03-31 | $-20.41M | (m) | (m) | $22.01M | (m) | (m) |
| 2019-12-31 | $-20.68M | $28.95M | (m) | $18.78M | (m) | -71.42% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-18.94M | (m) | (m) | $11.88M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-16.31M | (m) | (m) | $11.97M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |